Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven M Sparks

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
ACS Medicinal Chemistry Letters|July 18, 2019
Development of Highly Selective Pyrimidine-Based Aldosterone Synthase (CYP11B2) InhibitorsSteven M Sparks, Dana P Danger, William J Hoekstra, et al.
Bioorganic & Medicinal Chemistry Letters|September 17, 2017
Identification of potent, nonabsorbable agonists of the calcium-sensing receptor for GI-specific administrationSteven M Sparks, Paul K Spearing, Caroline J Diaz, et al.
Bioorganic & Medicinal Chemistry Letters|December 20, 2008
Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of Type 2 diabetes: 2. Optimization of serine and threonine ether amino acid residuesSteven M Sparks, Pierette Banker, David M Bickett, et al.
Bioorganic & Medicinal Chemistry Letters|June 3, 2014
Identification of diarylsulfonamides as agonists of the free fatty acid receptor 4 (FFA4/GPR120)Steven M Sparks, Grace Chen, Jon L Collins, et al.
Bioorganic & Medicinal Chemistry Letters|February 3, 2017
Exploration of phenylpropanoic acids as agonists of the free fatty acid receptor 4 (FFA4): Identification of an orally efficacious FFA4 agonistSteven M Sparks, Christopher Aquino, Pierette Banker, et al.
Bioorganic & Medicinal Chemistry Letters|March 19, 2011
Phenoxyacetic acids as PPARδ partial agonists: synthesis, optimization, and in vivo efficacyKaren A Evans, Barry G Shearer, David D Wisnoski, et al.
Bioorganic & Medicinal Chemistry Letters|December 20, 2008
Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes: 1. Identification of 1-amino-1-cycloalkyl carboxylic acid headgroupsSteven M Sparks, Pierette Banker, David M Bickett, et al.
Bioorganic & Medicinal Chemistry Letters|January 14, 2009
Anthranilimide based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes. Part 3: X-ray crystallographic characterization, core and urea optimization and in vivo efficacyStephen A Thomson, Pierette Banker, D Mark Bickett, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
ACS Medicinal Chemistry Letters|July 18, 2019
Development of Highly Selective Pyrimidine-Based Aldosterone Synthase (CYP11B2) InhibitorsSteven M Sparks, Dana P Danger, William J Hoekstra, et al.
Bioorganic & Medicinal Chemistry Letters|September 17, 2017
Identification of potent, nonabsorbable agonists of the calcium-sensing receptor for GI-specific administrationSteven M Sparks, Paul K Spearing, Caroline J Diaz, et al.
Bioorganic & Medicinal Chemistry Letters|December 20, 2008
Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of Type 2 diabetes: 2. Optimization of serine and threonine ether amino acid residuesSteven M Sparks, Pierette Banker, David M Bickett, et al.
Bioorganic & Medicinal Chemistry Letters|June 3, 2014
Identification of diarylsulfonamides as agonists of the free fatty acid receptor 4 (FFA4/GPR120)Steven M Sparks, Grace Chen, Jon L Collins, et al.
Bioorganic & Medicinal Chemistry Letters|February 3, 2017
Exploration of phenylpropanoic acids as agonists of the free fatty acid receptor 4 (FFA4): Identification of an orally efficacious FFA4 agonistSteven M Sparks, Christopher Aquino, Pierette Banker, et al.
Bioorganic & Medicinal Chemistry Letters|March 19, 2011
Phenoxyacetic acids as PPARδ partial agonists: synthesis, optimization, and in vivo efficacyKaren A Evans, Barry G Shearer, David D Wisnoski, et al.
Bioorganic & Medicinal Chemistry Letters|December 20, 2008
Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes: 1. Identification of 1-amino-1-cycloalkyl carboxylic acid headgroupsSteven M Sparks, Pierette Banker, David M Bickett, et al.
Bioorganic & Medicinal Chemistry Letters|January 14, 2009
Anthranilimide based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes. Part 3: X-ray crystallographic characterization, core and urea optimization and in vivo efficacyStephen A Thomson, Pierette Banker, D Mark Bickett, et al.
Pageof 2